Newcomer Dova hustles a pharma castoff through to an FDA approval, shares sink anyway
Less than a year after little Dova Pharmaceuticals popped up on Nasdaq to raise $75 million from an IPO, the biotech has raced ahead to an FDA approval of its lead drug.
Durham-based Dova picked up avatrombopag from Eisai for a song — plus $5 million up front. It was already Phase III ready at the time, allowing Dova to quick march to the marketplace.
The FDA offered a green light to use the drug — to be marketed as Doptelet — for a set of chronic liver disease patients suffering from low blood platelet counts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
